Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


Over the last decade, our research provides strong evidence that the drivers of minimal residual disease (MRD) survival are different from those that drive bulk ovarian cancer. Therefore, eliminating minimal residual disease at the end of traditional treatment requires rationalised therapeutics that specifically target MRD drivers. In this talk I will discuss our recent work in characterising MRD in ovarian cancer and our ongoing work to develop therapeutics to eliminate it.